Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking method to diabetes management. These innovative therapies function by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these agents enhance insulin release and suppress glucagon o

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing differences in their ph